M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate Pharmaceutical TechnologyThe deal provides BioMarin with a potential rival to AstraZeneca's blockbuster Strensiq in hypophosphatasia.Rare DiseaseRead full story pharminent August 19, 2026 (Last updated: August 23, 2026) Pharmaceutical Technology The deal provides BioMarin with a potential rival to AstraZeneca’s blockbuster Strensiq in hypophosphatasia. Rare Disease Read full story Post navigation Previous: Amylyx’s Avexitide Succeeds in Phase 3 Pivotal Study for Post-Bariatric HypoglycemiaNext: Trump nominates policy aide Overton to lead FDA Related Stories M&A / Deals Exegenesis Bio and Modalis sign research deal for Duchenne therapy pharminent September 11, 2026 M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026